Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Amgen Repatha Studies
Repatha is the Longest Studied PCSK9i
Amgen (AMGN) announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial. The studies were designed to assess the long-term safety and tolerability of Repatha over five years in adults with clinically evident atherosclerotic cardiovascular disease.

The FOURIER-OLE (Further . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.